1	An Oxford Nanopore-based Characterisation of Sputum Microbiota Dysbiosis in
2	Patients with Tuberculosis: from baseline to 7 days after Antibiotic Treatment
3	John Osei Sekyere [#] , Nontuthuko E. Maningi, Siphiwe Ruthy Matukane, Nontombi M.
4	Mbelle, Petrus Bernard Fourie [#]
5	Department of Medical Microbiology, School of Medicine, Faculty of Health Sciences,
6	University of Pretoria, South Africa.
7	#Address correspondence to Dr. John Osei Sekyere (jod14139@gmail.com) or Professor P
8	Bernard Fourie (bernard.fourie@up.ac.za), Department of Medical Microbiology, University
9	of Pretoria.
10	
11	Running head: Antibiotic-based dysbiosis in TB patients
12	Tweet : "Oxford Nanopore's MinION sequencer can be a useful tool for diagnosing
13	tuberculosis and other polymicrobial infections, identifying resistance genes and mobile
14	genetic elements, and monitoring treatment and its effect on the host's microbiome"
15	Author summary
16	Tuberculosis (TB), one of the major killers of mankind, continually remains elusive as
17	challenges with early diagnosis and treatment monitoring remain. Herein, we use a single
18	portable sequencer from Oxford Nanopore, the minION, to diagnose TB and monitor its
19	treatment with antibiotics using routine sputum samples. In addition, the presence of other
20	pathogens, important commensals, antibiotic resistance genes, mobile genetic elements, and
21	the effect of the antibiotic treatment on the sputum microbiota were determined from the
22	same data. This makes the minION an important tool that can be used in clinical laboratories
23	to obtain data that can inform live-saving decisions.

24 Abstract

Background. Diagnostics for tuberculosis (TB) and treatment monitoring remains a
challenge, particularly in less-resourced laboratories. Further, the comprehensive sputum
microbiota of TB patients during treatment are less described, particularly using long-read
sequencers.

Methods. DNA from sputum samples collected from newly-diagnosed TB patients were
sequenced with Oxford Nanopore's MinION. MG-RAST and R packages (Phyloseq,
Microbiome) were used to determine the OTUs abundances, α/β diversities, functional
components, OTUs networks and ordination plots. Statistical significance of the generated
data was determined using GraphPad.

34 Results & conclusion. Antibiotics reduced the abundance and functional subsystems of each 35 samples' microbiota from baseline until day 7, when persistent, tolerant, and resistant 36 microbiota, including fungi, grew back again. Variations in microbiota abundance and 37 diversity were patient-specific. Closer microbiome network relationships observed in baseline 38 samples reduced until day 7, when it became closer again. Bacterial microbiota networks and 39 spatial ordination relationships were closer than that of other kingdoms. Actinobacteria 40 phylum and Mycobacterium were more affected by antibiotics than other phyla and genera. 41 Parasites, viruses, and fungi were less affected by antibiotics than bacteria in a descending 42 order. Resistance genes/mechanisms to important antibiotics, plasmids, transposons, insertion 43 sequences, integrative conjugative elements were identified in few samples. 44 MinION can be adopted clinically to monitor treatment and consequent dysbiosis, and 45 identify both known and unknown pathogens and resistance genes to inform tailored

46 treatment choices, specifically in TB.

47 Keywords: Mycobacterium tuberculosis; microbome; treatment monitoring; diagnostics;
48 metagenomics.

49 Introduction

50 Tuberculosis (TB), shall we ever overcome it? This question has been ringing through the 51 annals of history over several millennia among diverse cultures and regions as the 'white 52 plague' continues to devastate humanity and elude total eradication; a conundrum that still baffles clinicians, particularly with the current advancements in modern medicine 1-3. 53 54 Tuberculosis remains the deadliest infectious disease caused by a single aetiological agent, 55 *Mycobacterium tuberculosis* (MTB), which is an acid-fast bacilli and intracellular bacterial 56 pathogen ⁴⁻⁶. In 2019, 1.4 million people died from TB alone, including 208,000 who had HIV⁷. Whereas TB is treatable and curable with first-line drugs such as isoniazid (INH) and 57 58 rifampin (RFP), multidrug-resistant TB (MDR-TB), which was found in 206 030 people 59 globally in 2019, requires more toxic, expensive, and scarce second-line chemotherapeutic agents that are taken for two years 5,7-9. 60

61 Until recently, the lung microbiome was believed to be sterile. However, the advent of nonculture-based techniques has shown the presence of a stable microbiota in the lung 6,10 . 62 Furthermore, increasing evidence suggests that the intestinal microbiome modulates the lung 63 microbiome through immune system regulation, development and inducement ^{11,12}. Several 64 65 studies have shown that TB antibiotics, although taken orally, affect the upper and lower airways microbiome^{4,6}. This interaction between the gut-lung microbiome is mediated 66 67 through the immune system, and is being harnessed to enhance the treatment of asthma, 68 cystic fibrosis, chronic obstructive pulmonary diseases (COPD) through the administration of 69 probiotics and prebiotics that confers a microbiota than regulates inflammatory responses in the lungs ^{11–14}. Specifically, *Lactobacillus plantarum*, a gut commensal, has been shown to 70 reverse TB progression and pathologies in the lungs ⁶. A few studies have proposed the 71

presence and possible adoption of signature microbiota species that are indicative of the
presence of TB and can be used for detection and treatment monitoring ^{15,16}. However, this is
yet to be established and adopted as some studies also suggest otherwise ¹⁷.

75 The emergence and declining costs of whole-genome sequencing (WGS), with its varied applications in metagenomics ^{18,19}, and meta-transcriptomics ^{20,21}, are revolutionizing 76 molecular biology research. Particularly, metagenomics promises a faster and more efficient 77 78 detection of MTB infections and mixed infections, resistance profile, lineage of MTB strains, 79 and epidemiological spread of TB outbreaks for efficient management and control of TB ^{1,18,22,23}. Thus, several propositions have been made to adopt WGS as a diagnostic tool for 80 MTB in the clinical microbiology laboratory ^{1,18,22,23}. Of the 14 studies describing the 81 82 microbiome of sputum samples from TB patients at the time of writing, none have so far used 83 long-read sequencers such as Oxford Nanopore Technology's (ONT) MinION. All the 84 reported studies either used Roche's 454/GS FLX-Titanium (pyrosequencing) or Illumina's Miseq/Hiseq to sequence the 16s rRNA $^{24-28}$. Only one study has so far undertaken a shot-gun 85 metagenomic analysis of bronchoalveolar lavage (BAL) samples of TB patients ²⁹. 86 87 Hence, this study is the first to use a long-read sequencer to describe the sputum microbiota 88 of TB patients. We show that the MinION can be adopted in clinical laboratories as a 89 diagnostic tool to detect pathogens, monitor treatment outcomes and microbiota changes, and 90 identify resistance genes/mutations and mobile genetic elements (MGEs).

91 Methods

92 Study design and sampling

⁹³ This was a prospective study carried out at a TB clinic based at Stanza Bopape, Pretoria,

South Africa, in 2019. Twenty-one patients were recruited between June and August 2019 for

the study. Participants were persons newly confirmed to have pulmonary TB (using

96 GeneXpert), but who were not yet on treatment. Sputum samples were collected from each 97 participant at four different timepoints: baseline (day 0), day 1, day 2, and day 7. Baseline 98 samples were collected prior to the beginning of antibiotic therapy whilst days 1, 2, and 7 99 samples were collected one day, two days, and seven days after starting antibiotic treatment. 100 As the patients were all newly diagnosed with TB, they were placed on fixed-dose 101 combination (FDC) treatment involving first-line anti-TB drugs i.e., rifampicin, isoniazid, 102 pyrazinamide, and ethambutol. Demographic data of the patients viz., age and sex, were also 103 collected.

104 Sample treatment and sequencing

105 The collected sputum samples were transferred into the mycobacteriology laboratory 106 (University of Pretoria) in wrapped sputum containers and stored at -4 ° Celsius. The samples 107 were divided into two and one part was immediately dissolved in PrimeStore® Molecular 108 Transport Medium (MTM) for long-term storage. Another part was immediately used for 109 DNA extraction using the Ultra-Deep Microbiome Prep kit (Molzym GmbH & Co. KG, 110 Bremen, Germany), which depletes host DNA and enriches microbial DNA. The extracted 111 DNA was analysed using a NanoDrop spectrophotometer and gel electrophoresis to 112 determine their quality, quantity, and length.

113 ONT's Rapid Barcoding Sequencing kit, SQK-RBK004, was used to prepare the DNA

114 libraries for MinIon sequencing, following the recommended protocol. Briefly, the DNA

115 (~400ng) of 12 samples were transferred into 12 DNA LoBind tube and adjusted with

nuclease-free water up to 7.5µL; 2.5µL of Fragmentation Mix RB01-12 was added to make

117 up to 10μ L. The tubes were flicked gently to mix the contents and incubated at 30 °C (for 1

118 min) and at 80 °C (for 1 min) to simultaneously fragment and tag the DNA with unique

119 barcodes. The barcoded samples were then pooled into one 2 mL Eppendorf tubes and

120 washed with AMPure XP beads and a magnetic rack to purify the barcoded DNA.

- 121 Subsequently, 1 µL of RAP was added to 10 µL of pooled barcoded DNA, incubated for 5
- minutes, and mixed with 34 μ L of sequencing buffer, 25.5 μ L of loading beads, and 4.5 μ L

123 of nuclease-free water prior to loading into an already primed MinION FLO-MIN 106D

124 R9/R10 flow cell. The sequencing was done for 12 hours per batch of 12 pooled barcoded

samples. This was repeated for the other samples in batches of 12.

126 Bioinformatics and statistical analysis

- 127 The generated Fast5 sequences reads were de-barcoded into individual sample DNA and
- 128 converted into FastQ files using the MinKNOW and EPI2ME applications provided by ONT.
- 129 Sequence reads with coverage below 10X were deleted/removed. Initial taxonomy and
- resistance determinants in each sample were provided by EPI2ME. The FastQ files were
- assembled into FastA files using Canu 2.1 on Ubuntu 18.04LTS using default parameters.
- 132 The assembled FastA files were uploaded to ResFinder
- 133 4.1(<u>https://cge.cbs.dtu.dk/services/ResFinder/</u>) /ResFinderFG 1.0
- 134 (https://cge.cbs.dtu.dk/services/ResFinderFG/), PlasmidFinder 2.1
- 135 (https://cge.cbs.dtu.dk/services/PlasmidFinder/), and Mobile Element Finder
- 136 (https://cge.cbs.dtu.dk/services/MobileElementFinder/) databases to determine resistance
- 137 mechanisms, plasmids, and mobile genetic elements respectively in the assembled reads.
- 138 The FastQ files were uploaded to MG-RAST ³⁰, from where the distribution of functional
- 139 categories for COGs, KOs, NOGs, and Subsystems, alpha diversities, rarefaction curves,
- taxonomies, sequence length histogram, and sequence GC contents per sample were obtained.
- 141 Operational taxonomic units (OUT), metadata, and taxonomy tables were built from the MG-
- 142 RAST data and used for downstream analyses in R using Phyloseq³¹ and Microbiome
- 143 (http://microbiome.github.com/microbiome) packages. The Chao1 and Shannon indices
- 144 (alpha diversity), abundance of each taxonomy per sample, non-metric multidimensional
- scaling (NMDS), and ordination of the various taxa per sample were obtained using

- 146 Microbiome, Phyloseq³¹, tidyr (<u>https://tidyr.tidyverse.org/</u>), dplyr (<u>https://cran.r-</u>
- 147 project.org/web/packages/dplyr/vignettes/dplyr.html), and ggplot2
- 148 (<u>https://ggplot2.tidyverse.org/</u>) packages in R.

149 Beta diversities were manually calculated using the formula $\beta = (S1-c) + (S2-c)$, where β is

- the beta diversity, S1 is the total number of species in the first environment, S2 is the total
- number of species in the second environment, and c is the number of species that the two
- 152 environments have in common. β diversities between samples from the same and different
- 153 patients were thus calculated.
- 154 The significance of each taxa abundance across samples, of alpha and beta diversities per
- sample and between samples, and of archaea, bacterial phyla, viral, fungal, and parasitic taxa
- across samples were determined using Wilcoxon's signed rank test, one sample t test, and
- 157 one-/two-way ANOVA. Descriptive statistics, row means, and variance were also determined
- using column statistics. All statistical analysis were carried out using GraphPad Prism 9.1.0
- 159 (221); p-values of <0.05 were defined as significant.

160 *Ethical clearance*

- 161 Ethical approval was provided by the Human Research Ethics Committee, Faculty of Health
- 162 Sciences, University of Pretoria, South Africa. All protocols and consent forms were
- 163 executed according to the agreed ethical approval terms and conditions. All clinical samples
- 164 were obtained directly from patients, who agreed to our using their specimens for this
- 165 research. The guidelines stated by the Declaration of Helsinki for involving human
- 166 participants were followed in the study.

167 Data availability

168 This Whole Genome Shotgun project has been deposited at DDBJ/ENA/GenBank

- under the Bioproject accession PRJNA673633 and Biosample accessions JAFMQ-
- JAFJNR000000000. The versions described in this paper is version JAFMQ-JAFJNR010000000.

172 **Results**

173 Demographics and Sequencing reads

The study recruited 21 patients, aged between 23 and 55 years with an average age of 37.41

175 years and median age of 38 years. Six of the patients were females whilst 15 were males,

- 176 with the females and males having a respective mean age of 30.60 and 40.25 years (Figure
- 177 1A; Dataset 1). Only 11 out of the 21 patients provided sputum samples within the time
- 178 frame of the study. Complete sputum samples i.e., sputum samples collected at baseline, day
- 179 1, day 2, and day 7, were obtained from seven patients whilst three patients provided samples
- at baseline, day 1, and day 2. One patient provided only baseline and day 7 sputum samples
- 181 (Fig. 1C). Only nine of the 11 sequenced reads qualified for inclusion in downstream analysis
- 182 owing to their higher coverage (>10X) (Fig. 1D; Dataset 1). The sequence lengths ranged
- from 1529 \pm 738bp to 3396 \pm 1305bp whilst the mean GC contents ranged from 40 \pm 5% to
- 184 50±10% (Dataset 1).

185 Taxonomy, abundance, & diversities

- A of total 40 phyla comprising 347 genera, belonging to Bacteria (n=258), Fungi (n=50),
- 187 Eukaryota (n=11), Animalia/Metazoa (n=8), Archaea (n=4), Plantae (n=3), Protista (n=2),
- and Chromista (n=1) were identified in the sputum samples (Dataset 2); variations in
- abundance for these kingdoms across samples were statistically significant. A core
- 190 microbiota of 56 genera, which were present in at least 70% of all samples, was identified.
- 191 The count of each genus for all the samples, categorised into abundances above 1000,
- between 100 and 1000, between 10 and 100, and below 10, showed that most genera fell

193	below a total abundance of 10 whilst a few fell above a total abundance of 1000.
194	Streptococcus (p-value: 0.0078; <0.0001), Actinomyces (p-value: 0.1245; <0.0001),
195	Mycobacterium (p-value: 0.1149; <0.0001), Granulicatella (p-value: 0.0432; <0.0001),
196	Atopobium (p-value: 0.0078 <0.0001), Meyerozyma (p-value: 0.318; <0.0313), Rothia (p-
197	value: 0.1853 <0.0001), Catonella (p-value: 0.0884; <0.0001), Penicillium (p-value: 0.3076;
198	<0.0078), Lactobacillus (p-value: 0.0272 <0.0001), Gemella (p-value: 0.0902; <0.0001),
199	Veillonella (p-value: 0.2216; <0.0001), Candida (p-value: 0.0612; <0.0001), Pseudomonas
200	(p-value: 0.0147; <0.0001), and Propionibacterium (p-value: 0.1174; <0.0001) were among
201	the most dominant genera, with OTU abundance above 1000, in all samples (Figure S1).
202	The abundance of each OTU differed per sample, with baseline samples (D0) from patient
203	104 having the highest abundance. Notably, baseline samples from patients 104, 105, 107,
204	108, and 112 were higher than subsequent samples from days 1, 2, and 7 except in samples
205	from patients 109 and 117 where baseline samples had lower genera abundance than samples
206	from subsequent days (Fig. 2A; p-value: 0.005; <0.0001). Interestingly, samples from day 7
207	had higher OTU abundance than those from days 1 and 2, except in patients 107 (Fig. 2A).
208	The absolute counts of the genera (diversity) per sample showed unique characteristics per
209	patient. For instance, there were more diverse kinds of genera in baseline samples than
210	samples from days 1 and 2 in patients 104 and 108, as well as than day 1 samples in patients
211	105, 107, 112, and 117. However, baseline samples were lower than samples from
212	subsequent days in patient 109 (Fig. 2B). The highest genera count was in sample 108D0 (p-
213	value: <0.0001).

Alpha and Beta diversities

The variation in alpha diversity (provided by MG-RAST) in samples from each patient was
not consistent across patients; each patient had a unique variation in alpha diversity (p-value:

<0.0001). Specifically, there were variations in alpha diversities between samples from the
same patient, but in patients 105, 108, 109, 111, 112, and 117, there was an increase in alpha
diversities from either baseline or day 1 up to days 2 or 7 (Fig. 2C). The alpha-diversities
were different from the absolute count of genera types per samples, which tended to follow a
u-shaped pattern per patient (Figure 2B-C).

222 The Chao1 and Shannon alpha diversities (provided by Phyloseq) of each sample were not 223 the same and also differed within patients (Figure S1). Whereas the alpha diversities between 224 samples of the same patient were very close in the Chao1 index, they varied widely from 225 each other in the Shannon index. Using the Chao1 index, there was a general reduction in 226 alpha diversity of samples from baseline to days 1 and 2, except in patient 109. However, 227 there was a rise in alpha diversity of the samples at day 7 after a drop in days 1 and 2. In 228 patient 109, there was a rise in alpha diversity from baseline to day 1, after which the alpha 229 diversity dropped from day 2 to day 7. Furthermore, in patient 117, the baseline diversity was 230 higher than that on day 7. Patient 107 had a higher alpha diversity on day 2 than days 0 231 (baseline) and 1.

232 A similar pattern was observed in the Chao1 alpha diversity of bacterial genera in the 233 samples. Generally, there was a drop in Chao1 alpha-diversity from baseline to days 1 and 2 234 samples whilst day 7 samples had higher alpha-diversity than baseline, day 1, and day 2 samples, suggesting a growing of drug-resistant/tolerant species during the 7th day. The 235 236 exception was observed in patient 117 where day 7 samples had lower alpha-diversity than 237 baseline samples. Similarly, patient 107 had days 1 and 2 samples having higher alpha-238 diversities than baseline samples (Figure S2). However, the Chao1 and Shannon alpha-239 diversities of fungi, parasites/protozoa, and virus in the various samples showed relatively 240 minor, little or no differences at all (Fig. S2.vii-ix).

241	A comparison of both Chao1 and Shannon alpha diversities of baseline and days 1, 2, and 7
242	samples from all patients are also shown in Fig. S2(iii-vi). For samples collected at any given
243	timepoint (baseline, days 1, 2, and 7), there were variations between patients, highlighting
244	personal microbiome diversity.
245	Figure 2B shows the β -diversities (differences in genera diversities) between different
246	samples from the same patient (p-values: < 0.0001). The chart shows that there were
247	variations in genera diversity between samples from different time points i.e., baseline (S1),
248	day 1 (S2), day 2 (S3), and day 7 (S4), in all patients. Particularly, β -diversities of samples
249	from patients 108 and 107 were very high, followed by that of patients 111, 109, 112, 117,
250	105, and 104. In patient 107, the β -diversity between days 0 and 1 (S1 S2) samples were very
251	low compared to that of days 0 and 2 (S1 S3), days 0 and 7 (S1 S4), days 1 and 2 (S2 S3), and
252	days 2 and 7 (S3 S4). However, in patient 108, inter-sample β -diversity was highest between
253	days 0/baseline and 7 (S1 S4), days 0 and 1 (S1 S2), and days 0 and 2 (S1 S3). The inter-
254	sample β -diversities variation per patient were not as relatively vast as that of patients 107
255	and 108.
256	The inter-patient samples β -diversities showed that the largest variations occurred in baseline

samples from the different patients (blue bars in Fig. 2C). Specifically, β -diversity variations

between samples of patient 108 and other patients were distinctly wide (p-value: <0.0001).

Also notable were variations between days 2 (S3|S3) and 7 (S4|S4) samples' genera (Fig.

260 2C).

261 *Kingdom-specific abundances*

Analysis of the proportion of each kingdom in each collected sputum microbiota is presented in Figures 3A and S3. There were five main kingdoms viz. archaea, bacteria, virus, fungi, and parasites (protista), and minor kingdoms such as eukaryota, and animalia (metazoa). Bacteria

265	was the most dominant kingdom across all samples (p-value: <0.0086; < 0.0001) except in
266	107D2, 109D1, and 109D2, where fungi was most dominant (p-value: 0.2068; <0.0001).
267	Parasites were also found in substantial proportions in 104D1, 105D2, 107D7, 108D1,
268	108D2, 109D1, 109D2, and 112D2 (p-value: <0.0047; <0.0001), but viruses (p-value:
269	0.0332; <0.0001) and archaea (p-value: 0.3277; >0.999) were very minor in abundance in all
270	the samples (Fig. 3A & S3). A detailed breakdown of each phylum, class, order, family, and
271	genus in each sample across all time points and in only baseline, day 1, 2, and 7 samples are
272	shown in Figure S3.
273	Among Bacteria, the most common phyla were Firmicutes (p-value: 0.0069; <0.0001),
274	Actinobacteria (p: 0.0348; <0.0001), Proteobacteria (p: 0.0066; <0.0001), and Bacteriodetes
275	(p: 0.0037; <0.0001) (Fig. 4). In almost all the samples, the bacterial phylum Firmicutes was
276	the most dominant, except in 105D2, 107D2, 108D1, and 112D2 where it was almost absent.
277	Actinobacteria was the next dominant phylum, with Proteobacteria, Bacteroidetes and the
278	other phyla occupying a relatively small portion of the microbiota. A reduction in bacterial
279	phyla abundance was seen after the baseline until day 7, when a rise in abundance was
280	observed again in all the samples (Fig. 3B). The most abundant genera were Streptococcus,
281	followed by Mycobacteria (sea-blue bar), Actinomyces (orange bar), Pseudomonas (purple
282	bar), and Rothia (mauve). Bacilli, Alphaproteobacteria, Actinobacteria,
283	Epsilonproteobacteria, and Gammaproteobacteria were common bacterial classes whilst
284	Clostridiales, Actinomycetales, Lactobacillales, Burkholderiales, and Micrococcales were the
285	commonest bacterial orders that changed in abundance over the different time points (Fig.
286	S4).
287	A u-shaped pattern was observed among bacterial genera in the various phyla (Fig. 4): the
288	abundance of the genera reduced from baseline and rose gradually from day 2 to day 7.

- 289 Genera diversity were not consistent from baseline to day 7; it was patient specific (Fig. 4).

290	This decline in abundance among the genera is more clearly observed in Figure 5; but
291	Mycobacterium continued declining after the baseline value (p: <0.0001). Detailed
292	breakdown of all bacterial taxonomic ranks and OTUs per sample collection time are
293	provided in Fig. S4.

Archaea was only present in 108D0 (baseline sample) and included only four genera:

295 Ferroglobus, Methanocaldococcus, Methanococcus, and Methanosaeta (Fig. 6A); none of the

abundance variations of these genera were statistically significant. Fifteen genera were

identified in all samples as parasites, with Codonosigidae (p: 0.0612; <0.0001) and

298 Schistosoma (p: 0.0014; <0.0001) being the most abundant and common. Notably, the

variations in abundance in parasitic genera were not consistent between baseline and days 1,

2, and 7; most of these genera had non-significant variations in abundance (Dataset 3). In

patient 104, there was a reduction in abundance in parasitic genera from baseline to day 7, but

this was not the case in other patients. In 105, there was a rise in parasitic genera on day 2

and a fall on day 7. In 107, there was a sharp fall in parasitic genera abundance on day 1, a

304 gradual rise on day 2, and a sharp rise on day 7, which was higher than that of the baseline.

Similarly, a sharp rise in parasitic genera was observed on days 1 and 7 in 109. However, a

306 gradual rise in parasitic genera was observed in 108 up to day 2, when it dropped

significantly on day 7 (Figure 6B).

308 Under parasites were kingdoms such as Animalia, Chromista, Eukaryota, Metazoa, and

309 Protista, which varied across the different time points after commencement of antimicrobial

310 chemotherapy. Further breakdown of the various taxonomic ranks under these kingdoms per

sample is shown in Figure S5.

Unlike parasites, fungi were not found in all samples although there were 51 fungal genera,

313 making them the second most common kingdom after bacteria. Specifically, fungi were

314 absent from patient 104, and in samples 105D0, 107D0, 107D1, 108D1, 108D2, 109D7 and 315 117D7. Saccharomyces (p: 0.0821; 0.0078) was a common fungi genus in the samples, 316 particularly in 105D2, 105D7 and 106D7. Other common fungi genera were Penicillium (p: 317 0.3076; 0.0078), Meyerozyma (p: 0.318; 0.0313), and Debaryomyces (p: 0.163; 0.0625). 318 Variations in abundance and diversity of fungal genera were observed across different time 319 points in some samples, but none of the genera had significant variations in abundance across 320 the samples (Dataset 3). Particularly, there was a sharp rise in Saccharomyces in 105D2 and 321 105D7, albeit there was none in the baseline, suggesting that it increased in the microbiota 322 after antibiotics were introduced. There was a drop in abundance of Penicillium from 107D2 323 to 107D7 whilst several fungal genera such as Meyerozyma and Saccharomyces emerged, 324 increasing the diversity. Changes in fungal abundance and diversity were also observed in 325 patients 108, 109, and 111 (Fig. 6C). Detailed breakdown of fungal genera per sample 326 according to taxonomic rank is shown in Figure S6. 327 Viruses from Siphoviridae were the commonest and most abundant in all samples, 328 particularly baseline samples from patients 104, 107, 108, 112, and 117 as well as day 7 329 samples from patients 105, 106, 107, 108, 109, and 117. Notably, viruses, including 330 Siphoviridae, were almost absent in days 1 and 2 samples, except in 105D2, 107D2, and 331 111D1. Myoviridae, Podoviridae, and T4-like viruses were also present in mainly baseline 332 samples and to a lesser extent, day 7 samples, from patients 105, 106, 107, 108, 112, and 117; 333 107D2 was the only day 2 sample with these viruses (Fig. 6D). None of the viral OTUs had 334 significant variations in abundance across the samples (Dataset 3). Detailed viral OTUs per 335 taxonomic rank in each sample is detailed in Figure S7.

336 Functional subsystems components

337 A functional subsystem component analyses (generated by MG-RAST) showed the

338 proportional changes in key cellular processes and components in each sputum sample from

339 baseline through days 1, 2, to 7. Instructively, the functional component of each sample was 340 strongly/significantly associated with its abundance in that sample (Dataset 3). The major 341 functional subsystems in all the microbiota samples were clustering-based subsystems, 342 carbohydrates, protein metabolism, DNA and RNA metabolism, cofactors, vitamins, 343 prosthetic groups & pigments, and cell wall and capsules. Baseline and to some extent, day 7, 344 samples had the most abundant and diverse functional subsystems compared to those of days 345 1 and days 2. The functional components of the sputum microbiota decreased from baseline 346 to day 2 and increased gradually on day 7. An exception was observed in samples 109 and 347 117, in which day 7 samples had higher abundance and diversity of functional components 348 than the baseline samples (Fig. 7).

349 Network and ordination analysis

350 The spatial relationship and networking between the microbiota in the sputum samples

351 collected at different time points showed a reduction in the microbial networks from baseline

to day 7, with a thickening of the networks on day 7. The closer connection seen in the

networks shows the close interactions between the microbiota. Compared to bacteria,

network analyses for parasites were relatively less busy and interconnected. The changing

diversity of the phyla or classes (OTUs) in the collected samples at different time points is

also seen in the widening network distances and reducing interconnections between the

357 various classes (OTUs) (Figures 8, S9 and S10).

358 In the nonmetric multidimensional scaling (NMDR) ordination plots, a closer spatial

relationship existed between bacteria than fungi, virus, and parasite OTUs.

360 Gammaproteobacteria, Bacilli, Erysipelotrichia, Clostridia, and Actinomycetes, filled distinct

361 spaces distant from other classes that clustered together. The greatest change in ordination

362 was seen in bacterial classes. The day 1 ordination was closer to each other than the baseline

plots. Virtually no change was observed between the classes of other kingdoms in day 1 andbaseline (Fig. S10).

365 *Resistance genes and mobile genetic elements*

- Resistance determinants to tetracyclines (*tet*), aminoglycosides (*aph*, *aac*(2'), *aac*(3')),
- 367 macrolides (*erm*, *mef*, *msr*), quinolones (*qnrD*, unknown *gyrAB* mutations), isoniazid (*kat*G:
- 368 N138T, K143T, Y155S), capreomycin (*tly*A: A67E), para-aminosalicylic acid (*ribD*: G8R),
- 369 rifampicin (*rpoC*: F6V, F7A, L10H, W23R, S24*), ethionamide (ethR: R19?, D96G, R164?,
- T165?), pyrazinamide (*pncA* mutations), and ethambutol (*embR* mutations) were found in
- only eight sputum samples. Mobile genetic elements such as plasmids (ColRNAI, repUS38,
- repUS43, rep5e, repUS34), transposons (Tn253), integrative conjugative element (ICE) and
- insertion sequences (IS30, ISL, IS3, IS4, IS1182) were also found either alone or in
- association with antibiotic resistance determinants in 13 samples (Dataset 2).

375 Discussion

In this work, we show how ONT's MinION can be used to monitor the treatment outcome of

377 TB, detect MTB and other associated bacterial, fungal, parasitic, and viral pathogens, identify

antimicrobial resistance determinants and mobile genetic elements, and monitor microbiota

- 379 changes (dysbiosis) during antimicrobial chemotherapy using sputum. Hence, the importance
- of using this portable technology in clinical settings to diagnose infections, inform

antimicrobial treatment choices, monitor the effects of antimicrobials on the gut, oral, upper

382 airways and lungs microbiota, despite its inherent challenges, cannot be gainsaid.

383 Using sputum samples from patients freshly diagnosed with tuberculosis, it was observed that

- the microbiota of the sputum samples collected prior to the initiation of antibiotic therapy
- 385 (baseline samples) comprised of more diverse and abundant microbial genera (OTUs) than
- that observed in days 1, 2, and 7 (Fig. 2-6). Albeit there were a few exceptions to this pattern,

the higher abundance and diversity of microbiota in the sputum of untreated patients testify to the effect of antitubercular drugs on the sputum microbiota. Thus, although the antibiotics are taken orally, they become bioavailable in the sputum through the blood.

390 It is interesting to note that the microbial abundance and diversity began to increase on day 7 391 after onset of treatment, suggesting the regrowth of persistent, tolerant or resistant microbiota 392 after day 7 of treatment. However, this was not observed with Mycobacterium, which 393 continued declining even after day 7. This is expected because the antibiotics given to the 394 patients, i.e. isoniazid, rifampicin, pyrazinamide, and ethambutol, are narrow-spectrum 395 antibiotics targeting Mycobacterium. Notwithstanding the narrow spectrum nature of these 396 antibiotics, they did affect the abundance and diversity of the microbiota, including bacteria, 397 fungi, parasites, and viruses, although their effect on non-bacterial microbiota were relatively 398 limited (Figure 2-5). Recently, Kateete et al. (2021) observed a significant mean reduction in 399 the microbiotia biomass in the sputum of TB patients 2 months after onset of treatment. 400 Further, Sala et al. (2020) found non-significant changes in microbiota diversity in sputum of 401 TB patients up to 7 months. As the authors did not collect and analyse samples at day 7, a comparative analysis cannot be made ^{17,32}. 402

403 The change in microbial abundance and diversity after antibiotic treatment reflected in the 404 functional components subsystems dynamics, ordination plots and network analyses (Fig. 7-405 8; S8-S10). Particularly, the abundance of each functional subsystem in samples collected 406 from the same patient from baseline to day 7 also dropped on days 1 and 2, and rose on day 7 407 whilst the network relationship between the microbiota reduced from baseline samples until 408 they increased on day 7. This is expected, as the biocidal action of the antibiotics on the 409 microbiota will definitely reduce the number of microbes and their functions in the upper air 410 ways (Fig. 7). Hence, any beneficial effect of the microbial activity in the upper airways, 411 including the production of metabolites important to the host, will be negatively affected.

412 Further, the regrowth of the microbiota and the increase in their metabolic functions from day 413 7 suggests the evolution and emergence of tolerance, persistence, and resistance, which 414 numbs the effects of the antibiotics on these microbes. Further, the reducing microbial 415 abundance also reduced the spatial interrelationship between the microbes until day 7, when 416 they grew back and strengthened the networks between them again (Fig. S9-S10). This shows 417 the short-term effect of antibiotics in generating resistance and demonstrates why it is 418 inadvisable to use antibiotics beyond a week for normal infections. 419 The functional components and subsystems of the microbiota (Fig. 7) gives a comprehensive 420 overview of the cellular activities (metabolic pathways), components, and metabolites 421 produced by the microbiota. Notably, most of the samples were dominated by clustering-422 based subsystems (contain functions such as proteosomes, ribosomes and recombination-423 related clusters), carbohydrates, protein metabolism, RNA & DNA metabolism, amino acids 424 and derivates, co-factors, vitamins, prosthetic groups and pigments, cell wall and capsule, 425 fatty acids, lipids and isoprenoids, nucleotides and nucleosides, membrane transport, 426 virulence, disease and defence, phages, prophages, transposable elements and plasmids, and 427 regulation and signaling. Obviously, all these subsystems are necessary for the normal 428 functional activities of the cell, except prophages, transposable elements and plasmids, and 429 virulence, disease, and defence. Hence, most of the metabolic activities of the sputum 430 microbiota were focused on maintaining cellular life.

Other studies characterising microbial communities in termite mound soils³³, grassland soils ³⁴, and water reservoirs ³⁵, also found a similar composition and abundance in the microbial communities, confirming that these processes are basic to cellular life irrespective of the ecological niche. It's interesting that dormancy and sporulation structures were reduced to the basic minimum on day 1 and rose on day 7, limiting the possibility that antibiotic exposure could have increased dormancy and sporulation among the microbiota. Sharma et al. (2017)

437	observed a downregulation of MTB genes involved in ATP synthesis, aerobic respiration,
438	translational and section machinery, etc. whilst there was no differential expression in
439	dormancy genes (dosRS), suggestive of a low energy, low metabolism, and low replication
440	state in the sputum 36 .

The α -diversities show that each patient had a unique microbiome with different microbiota 441 442 composition and metabolic/functional subsystems that reacted quite similarly to antibiotics 443 (Fig. 2C & 7). The changing within-host α -diversities show that antibiotics affect the 444 microbial diversity (Fig. 2C). This is further corroborated by the inter-sample diversity within 445 and between hosts (Fig. 2D). In particular, samples from patients 107 and 108 were very 446 diverse from each other as well as from other samples. In all patients, changes between 447 baseline and days 1 and 2 samples were substantial (Fig. 2D-E), representing the significant 448 shift in diversity from baseline to days 1 and 2 after antibiotic treatment. A change in adiversity was also noticed recently in MTB+ patients BAL microbiome²⁹. Notably, some 449 450 authors have observed little or no differences in sputum microbiome diversity between TB and non-TB patients from non-Africa settings ^{17,28}. Specifically, the sampling points, 16s 451 452 rRNA and pyrosequencing used were different from that used herein. Hu et al. (2020) argue 453 that 16s rRNA-based analysis of TB-microbiome provides lower resolution than wholegenome shot-gun metagenomics²⁹. 454

455 The sputum microbiota was dominated by bacteria, followed by fungi and a few parasites,

456 viruses, and archaea. Firmicutes was the most abundant phylum among bacteria, followed by

457 Actinobacteria and Proteobacteria. Similar microbiota compositions, albeit with little shifts in

relative abundance, have been reported in other studies using 16s rRNA or shot-gun

459 metagenomics on either sputum or BAL from TB patients $^{15-17,25-29,32,36-41}$. Compared to the

460 dysbiosis in all the microbiota (Fig. 2), the bacterial dysbiosis was most pronounced, with a

substantial drop in abundance being observed on day 1 (Fig. 3). Streptococcus was the most

dominant genera in Firmicutes (Fig. 4)^{28,32,39,40}, whose abundance was also affected by the
antibiotic-mediated dysbiosis. In patient 105, Leuconostoc replaced Streptococcus as the
most dominant genera on days 1 and 2. In patient 104, Gemella, Clostridium,
Staphylococcus, Solobacterium, and Erysipelotrichaceae increased on day 1. Coprobacillus
increased in abundance in 108D1 and 108D2. Similar patterns were observed in almost all
samples, in which different genera emerged after a reduction in Streptococcus abundance
(Fig. 4A).

469 Unlike Firmicutes, no single genera dominated the phylum Proteobacteria, albeit

Pseudomonas was common in many samples (Fig. 4B)^{16,29,39}. Specifically, baseline and day 470 471 7 samples were dominated by Pseudomonas, suggesting that Pseudomonas was affected by 472 the antibiotics, but grew back on day 7. Neisseria was very common in 104D0, but virtually 473 absent in subsequent days, which also suggest that it was affected by the antibiotics. There 474 was a notable rise in Achromobacter in 107D1, but it diminished again on 107D1-D7, where 475 it was replaced by Pseudmonas, Klebsiella, and Proteus. These dynamics only confirm that 476 susceptible genera were giving way to more tolerant, persistent, and resistant Proteobacterial 477 genera.

The phylum Actinobacteria was dominated by Mycobacterium, Atopobium, Actinomyces,

and Rothia, which has been found by Hong et al. (2018) to be always co-occurring with MTB

480 ^{15,16,29}. Unlike the phyla Firmicutes and Proteobacteria, the effect of the antibiotics on

481 Actinobacteria were more drastic. This is not surprising as Mycobacterium, which these

antibiotics mainly target, are found within this phylum (Fig. 4C). Moreover, compared to the

483 other phyla, the members of this phyla did not grow back on day 7; except 108D7. Thus, anti-

484 mycobacterial drugs were more effective against Actinobacteria than other phyla (Fig. 4).

485 Other bacterial phyla, including Aquificae, Bacteroidetes, Fusobacteria, Fibrobacteres,

486 Chlorflexi, Cyanobacteria, Deinococcus-Thermus, Nitrospirae, Planctomycetes, Spirochaetes,

487 Synergistetes, Tenericutes, and Verrucomicrobia were also found in the sputum

- 488 microbiota^{28,29,32,39}. Among these phyla, the commonest were Bacteroidetes (Bacteroides,
- 489 Prevotella), Fusobacteria (Fusobacterium), Synergistetes, Spirochaetes (Treponema),
- 490 Tenericutes (Candidatus phytoplasmsa), and Cyanothece (Cyanobacteria). These phyla were
- 491 also affected by the antibiotics as their abundance and diversity dropped after baseline and

492 rose on day 7. However, in patients 107 and 108, these phyla increased in abundance on days

493 1 and/or 2 than on day 7, with shifts in genera diversity/composition, suggesting the

494 proliferation of resistant and/or persistent genera (Fig. 5).

495 An example of the MinION's ability to identify other potentially pathogenic genera is shown

496 in Fig. 5 where genera such as Streptococcus (Fig. 5A), Mycobacterium (Fig. 5B),

497 Clostridium, Schistosoma, Neisseria, Enterococcus, and Staphylococcus (Fig. 5E-F) were

detected. This makes the MinION a potential diagnostic tool that can be used to detect not

499 only *Mycobacterium tuberculosis* using sputum samples, but also other pathogens that inhabit

the oral and pharyngeal cavities. Particularly in polymicrobial or secondary infections, this

tool can help clinicians identify all pathogens in the patient's sample, informing appropriate

antimicrobial choices. Further, it can be used to monitor treatment in patients by measuring

the abundance of any pathogen over time. In this case, the efficacy of the antimicrobial

agents could be seen in the declining abundance of the various genera, including

505 Mycobacterium. When there is a regrowth of the targeted pathogen, in this case *M*.

506 *tuberculosis*, the clinician can see it and change the antibiotics used. Finally, the shifts in the

507 microbiota can also inform the clinician of the extent of antibiotics-mediated dysbiosis and its

508 potential effects on the immunity and emergence of other non-susceptible and diarrhoeagenic

pathogens such as *Clostridium difficile*, Shigella, *Escherichia coli* etc. that can complicate or prolong healing 6,24 .

511	There was a more significant effect of the antibiotics on parasites than on fungi and viruses
512	(Fig. 6; Dataset 3). Interestingly, in patients 105 and 107, the identified fungi genera only
513	grew after days 2 and 7, suggesting their proliferation after the decline in the bacterial
514	population. Similarly, in patient 108, the fungi found in the baseline samples all diminished
515	on days 1 and 2, only to be replaced with different fungi on day 7 whilst patients 109 and 112
516	had different genera replacing those found in their baseline samples. These observations
517	show that the antibiotics provided advantage to other fungal genera to outgrow others.
518	Codonosigidae and Cryptosporidium seemed tolerant and more resistant to the antibiotics
519	than the other parasites as they were able to grow on days 1 to 7 with little or no reductions
520	and substantial increments (Fig. 6; Dataset 3). Fungi belonging to Ascomycota and
521	Basidiomycota (Fig. S6) were detected in both sputum and oropharyngeal TB samples with
522	similar community structures ²⁶ ; however the effect of antibiotics on these phyla were not
523	described.
524	Although antibiotics have no effect on viruses, reductions were seen in the abundance of
525	Siphoviridae, Myoviridae, and Podoviridae. This could be an indirect effect through
526	antibiotics action on bacteria, fungi, and parasites, which could be serving as cellular hosts to

the viruses, which cannot exist outside of living cells. Therefore, the reducing abundance of

bacteria, fungi, and parasites could be ridding the viruses of important hosts in which they

can multiply, affecting their abundance as well. This demonstrates that antibiotics-mediated

microbiota dysbiosis can also affect the virome population. Hence, as the bacteria, fungi, and

parasites populations increased on day 7, that of the viruses also increased in tandem (Fig. 6;

532 Dataset 3).

527

528

529

530

531

533 The network analysis and ordination plots show that there is a closer interaction between 534 bacterial genera, including Mycobacterium, than between non-bacterial ones. This closer association was affected by antibiotics, evincing the effect of dysbiosis on the ecology of the 535 microbiome 4,6,24 . The effect of such an interaction, or its lack thereof, on the pathogenesis of 536 537 *M. tuberculosis* is yet to be established, although dysbiosis has been associated with 538 increased TB pathologies. Obviously, the beneficial effects of the microbiota and their 539 interactions on the immune system, including their production of metabolites, indirectly affects the pathogenesis of *M. tuberculosis* 4,6,24 . 540

541 Analysis of the microbiota across the samples shows the presence of external genera that are

not commonly found in or part of the core oral microbiome. Examples include

543 Stenotrophomonas, Cupriavidus, Sphingomonas, Brevibacillus, and the anaerobe, Lautropia

^{24,27}. Except for Lautropia and Brevibaccilus, the others were found in day 1 or 7 samples.

545 Whereas Naidoo et al. (2021) found an enrichment of Lautropia in sputa microbiota of

treatment-naïve TB patients, this was not the case in our data ²⁴. However, these observations

shows the invasion of external microbiota in the upper airway microbiome due to TB or

548 antibiotics therapy.

549 The antibiotic resistance mechanisms and MGEs of the microbiota in the sputum samples 550 were determined and found to be relatively few. It is noteworthy that all the recruited patients 551 were newly diagnosed with TB and were not found to have rifampicin or multidrug resistance by GeneXpert and the line probe ^{5,6,8,9,42}. However, an analysis of the microbiota identified 552 553 resistance-mediating mutations in genes that confer resistance to TB drugs such as 554 aminoglycosides, quinolones, isoniazid, capreomycin, rifampicin, ethambutol, ethionamide, 555 and pyrazinamide as well as to non-TB antibiotics in a few of the samples; particularly, 108D0^{5,8,9}. The absence of these mutations in subsequent samples could suggest that these 556

mutations were not enough to withstand the effect of all four antibiotics combined. Moreover,

557

this evidence shows that the MinION can not only detect the presence of Mycobacterium but
also its resistance profiles, and possibly lineage, in sputum samples, particularly when
sequenced at a higher coverage. The resistance mechanisms of the other microbiota and their
MGEs can also be determined to inform important clinical decisions.

Finally, the data suggests that age and sex had little to do with the outcome of the findings as same or similar patterns were observed in samples from different ages and sexes; findings by Wu et al. (2013) also concur ³⁹. Larger cohorts may be necessary in future studies to confirm the absence of any effect of age and/or sex on the sputum microbiota and its response to antitubercular therapy.

567 *Conclusion*

568 ONT's MinION sequencer is a portable device that can be used to detect Mycobacterium in

sputum samples of patients newly diagnosed with TB, monitor their response to treatment,

570 detect the presence of other pathogens (polymicrobial infections) in the sputum samples,

identify resistance genes and MGEs, and monitor the effect of administered antibiotics on the

572 sputum microbiota. With the introduction of advanced flow cells and kits that can multiplex

at most 96 samples (<u>https://store.nanoporetech.com/us/pcr-barcoding-expansion-1-96.html</u>),

it is even cheaper and faster to detect the presence of *M. tuberculosis* and other pathogens,

their resistance and virulence mechanisms as well as their MGEs in clinical samples within 6-

48 hours. The presence of other pathogens that may not be targeted by routine

577 microbiological assays, can be easily detected by the MinION, helping clinicians treat

polymicrobial and idiopathic infections. The sequence lengths produced by the MinION,

which ranged from 1500-4000bp, coupled with higher coverage, can enhance its sensitivity

580 and specificity for detecting all commensals and pathogens as well as their clones/lineages.

581 The comprehensive data provided by this new technology makes it ideal for clinical

582 microbiology laboratories to detect all pathogens with little laboratory accoutrements. We

show that the oral administration of anti-tubercular chemotherapy affects the sputum

microbiota by reducing their abundance and shifting their diversity from onset of treatment

585 (day 1) until day 7, when persistent, tolerant, and resistant microbiota, including fungi, begins

to grow back to replenish the microbiome. Hence, antibiotics usage after one week should be

587 done with caution as it can result in drug-resistant infections.

Funding sources: This study was funded by (1) South African National Research Foundation
Grant number UID 127338; (2) CRDFGlobal Grant number DAA9-20-66880-1.

590 Acknowledgement: We are grateful to the following persons for their help in this work. (1)

591 Patient screening: Sr Mkhondo, Stanza Bopape Community Health Centre TB Clinic,

592 Pretoria; (2) Field work and specimen collections: Ms Phindile Ntuli, Ms Sharon Olifant; (3)

593 Donation of PrimeStore Molecular Transport Medium: Longhorn Vaccines and Diagnostics,

San Antonio, TX (only if the product is mentioned in the manuscript).

595 We especially dedicate this work to the memory of Professor Nontombi Marylucy Mbelle

Ph.D., who passed away in January 2021, prior to the completion and submission of thiswork.

Transparency declaration: The authors declare no conflict of interest and the funders had
no influence or decision whatsoever in the decision to write-up and publish this work.

600 Author contributions: JOS designed and carried out all the laboratory (experimental),

601 sequencing, bioinformatics, and statistical aspects of this work. He also wrote the article and

formatted for publication. **NEM** and **SRM** assisted with the experimental sections of this

603 work. NMM assisted with funding and sequencing reagents for this work. PBF supervised

this work and provided funding for it. All authors reviewed this work prior to submission for

605 publication.

606 **References**

- Kay, G. L. *et al.* Eighteenth-century genomes show that mixed infections were common at time of peak tuberculosis in Europe. *Nat. Commun.* 6, 1–9 (2015).
- bonoghue, H. D. Insights into ancient leprosy and tuberculosis using metagenomics. *Trends Microbiol.* 21, 448–450 (2013).
- 611 3. Cambier, C. J., Falkow, S. & Ramakrishnan, L. Host Evasion and Exploitation Schemes of Mycobacterium tuberculosis. *Cell* 159, 1497–1509 (2014).
- 4. Naidoo, C. C. *et al.* The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda. *The Lancet Respiratory Medicine* 7, 892–906 (2019).
- 5. Osei Sekyere, J., Reta, M. A., Maningi, N. E. & Fourie, P. B. Antibiotic resistance of Mycobacterium tuberculosis
 complex in Africa: A systematic review of current reports of molecular epidemiology, mechanisms and diagnostics. *Journal of Infection* 79, 550–571 (2019).
- 6. Osei Sekyere, J., Maningi, N. E. & Fourie, P. B. Mycobacterium tuberculosis, antimicrobials, immunity, and lung–gut microbiota crosstalk: current updates and emerging advances. *Ann. N. Y. Acad. Sci.* 1467, 21–47 (2020).
- 620 7. WHO. Global Tuberculosis Report 2020. Who (2020). doi:WHO/HTM/TB/2017.23
- Maningi, N. E. *et al.* Multi- and Extensively Drug Resistant Mycobacterium tuberculosis in South Africa: a
 Molecular Analysis of Historical Isolates. *J. Clin. Microbiol.* 56, JCM.01214-17 (2018).
- 623 9. osei Sekyere, J., Maphalala, nontobeko, Malinga, L. A., Mbelle, nontombi M. & Maningi, nontuthuko E. A
 624 Comparative Evaluation of the New Genexpert MTB/RIF Ultra and other Rapid Diagnostic Assays for Detecting
 625 Tuberculosis in Pulmonary and Extra Pulmonary Specimens. *Sci. Rep.* 9, (2019).
- bickson, R. P. & Huffnagle, G. B. The Lung Microbiome: New Principles for Respiratory Bacteriology in Health and Disease. *PLoS Pathog.* 11, 1–5 (2015).
- Shukla, S. D., Budden, K. F., Neal, R. & Hansbro, P. M. Microbiome effects on immunity, health and disease in the lung. *Clin. Transl. Immunol.* 6, e133 (2017).
- 630 12. O'Dwyer, D. N., Dickson, R. P. & Moore, B. B. The Lung Microbiome, Immunity and the Pathogenesis of Chronic Lung Disease. *J Immunol* 196, 87–92 (2016).
- 13. Hauptmann, M. & Schaible, U. E. Linking microbiota and respiratory disease. FEBS Lett. 590, 3721–3738 (2016).
- Evsyutina, Y., Komkova, I., Zolnikova, O., Tkachenko, P. & Ivashkin, V. Lung microbiome in healthy and diseased individuals. *World J. Respirol.* 7, 39–47 (2017).
- Hong, B. young, Paulson, J. N., Stine, O. C., Weinstock, G. M. & Cervantes, J. L. Meta-analysis of the lung microbiota in pulmonary tuberculosis. *Tuberculosis* 109, 102–108 (2018).
- 637 16. Hu, Y. *et al.* Distinct lung microbial community states in patients with pulmonary tuberculosis. *Sci. China. Life Sci.*638 63, 1522–1533 (2020).
- 639 17. Sala, C. et al. Multicenter analysis of sputum microbiota in tuberculosis patients. PLoS One 15, e0240250 (2020).
- Boughty, E. L., Sergeant, M. J., Adetifa, I., Antonio, M. & Pallen, M. J. Culture-independent detection and characterisation of Mycobacterium tuberculosis and M. africanum in sputum samples using shotgun metagenomics on a benchtop sequencer. *PeerJ* 2, 1–18 (2014).
- 543 19. Zhang, Y., Lun, C. Y. & Tsui, S. K. W. Metagenomics: A newway to illustrate the crosstalk between infectious diseases and host microbiome. *International Journal of Molecular Sciences* 16, 26263–26279 (2015).
- 645 20. Martinez, X. et al. MetaTrans: An open-source pipeline for metatranscriptomics. Sci. Rep. 6, 1–12 (2016).
- Bashiardes, S., Zilberman-schapira, G. & Elinav, E. Use of Metatranscriptomics in Microbiome Research.
 Bioinform. Biol. Insights 10, 19–25 (2016).
- 648 22. Lee, R. S. & Behr, M. A. The implications of whole-genome sequencing in the control of tuberculosis. *Ther. Adv.*

649		Infect. Dis. 3, 47–62 (2016).
650 651	23.	Witney, A. A. <i>et al.</i> Clinical use of whole genome sequencing for Mycobacterium tuberculosis. <i>BMC Med.</i> 14 , 46 (2016).
652 653	24.	Naidoo, C. C. <i>et al.</i> Anaerobe-enriched gut microbiota predicts pro-inflammatory responses in pulmonary tuberculosis. <i>EBioMedicine</i> 67 , 103374 (2021).
654 655	25.	Eshetie, S. & Van Soolingen, D. The respiratory microbiota: New insights into pulmonary tuberculosis. <i>BMC Infect. Dis.</i> 19 , 1–7 (2019).
656 657	26.	Botero, L. E. <i>et al.</i> Respiratory tract clinical sample selection for microbiota analysis in patients with pulmonary tuberculosis. <i>Microbiome</i> 2 , 29 (2014).
658 659	27.	Cui, Z. <i>et al.</i> Complex sputum microbial composition in patients with pulmonary tuberculosis. <i>BMC Microbiol.</i> 12 , 276 (2012).
660 661	28.	Cheung, M. K. <i>et al.</i> Sputum Microbiota in Tuberculosis as Revealed by 16S rRNA Pyrosequencing. <i>PLoS One</i> 8 , e54574 (2013).
662 663	29.	Hu, Y. <i>et al.</i> Metagenomic analysis of the lung microbiome in pulmonary tuberculosis - a pilot study. <i>Emerg. Microbes Infect.</i> 9 , 1444–1452 (2020).
664 665	30.	Keegan, K. P., Glass, E. M. & Meyer, F. MG-RAST, a metagenomics service for analysis of microbial community structure and function. in <i>Methods in Molecular Biology</i> 1399 , 207–233 (Humana Press Inc., 2016).
666 667	31.	McMurdie, P. J. & Holmes, S. Phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. <i>PLoS One</i> 8 , e61217 (2013).
668 669	32.	Kateete, D. P. <i>et al.</i> Sputum microbiota profiles of treatment-naïve TB patients in Uganda before and during first- line therapy. <i>bioRxiv</i> (2020). doi:10.1101/2020.04.24.20078246
670 671	33.	Enagbonma, B. J., Amoo, A. E. & Babalola, O. O. Deciphering the microbiota data from termite mound soil in South Africa using shotgun metagenomics. <i>Data Br.</i> 28 , (2020).
672 673	34.	Delmont, T. O. <i>et al.</i> Structure, fluctuation and magnitude of a natural grassland soil metagenome. <i>ISME J.</i> 6 , 1677–1687 (2012).
674 675	35.	Soriano, B. M., Del Valle-Perez, L. M., Morales-Vale, L. & Rios-Velazquez, C. Datasets generated by shotgun sequencing of metagenomic libraries of the guajataca water reservoir. <i>Data Br.</i> 21 , 2531–2535 (2018).
676 677	36.	Sharma, S. <i>et al.</i> Transcriptome analysis of mycobacteria in sputum samples of pulmonary tuberculosis patients. <i>PLoS One</i> 12 , 1–16 (2017).
678 679	37.	Maiga, M. <i>et al.</i> Stool microbiome reveals diverse bacterial ureases as confounders of oral urea breath testing for Helicobacter pylori and Mycobacterium tuberculosis in Bamako, Mali. <i>J. Breath Res.</i> 10 , 36012 (2016).
680 681	38.	Vázquez-Pérez, J. A. <i>et al.</i> Alveolar microbiota profile in patients with human pulmonary tuberculosis and interstitial pneumonia. <i>Microb. Pathog.</i> 139 , 103851 (2020).
682 683	39.	Wu, J. <i>et al.</i> Sputum microbiota associated with new, recurrent and treatment failure tuberculosis. <i>PLoS One</i> 8 , e83445 (2013).
684 685	40.	Krishna, P., Jain, A. & Bisen, P. S. Microbiome diversity in the sputum of patients with pulmonary tuberculosis. <i>Eur. J. Clin. Microbiol. Infect. Dis.</i> 35 , 1205–1210 (2016).
686 687	41.	Lin, D. <i>et al.</i> Sputum microbiota as a potential diagnostic marker for multidrug-resistant tuberculosis. <i>Int. J. Med. Sci.</i> 18 , 1935–1945 (2021).
688 689	42.	Osei Sekyere, J. & Asante, J. Emerging mechanisms of antimicrobial resistance in bacteria and fungi: advances in the era of genomics. <i>Future Microbiol.</i> 13 , 241–262 (2018).
690		
691		

Figure 1. Demographic information and sputum sampling of recruited patients. The patients

were aged between 23 and 55 years, with a median age of 38 years and average age of 37.41

695 years (A). Six of the patients were females whilst 15 were males, with the females and males

- having a respective mean age of 30.60 and 40.25 years (**B**). Sputum samples collected at
- baseline, day 1, day 2, and day 7 were obtained from 7 patients whilst three patients provided
- samples at baseline, day 1, and day 2, and one patient provided only baseline and day 7
- sputum samples (C). Only nine of the 11 sequenced reads qualified for inclusion in
- downstream analysis owing to their higher coverage (>10X) (**D**).

Figure 2. Count and abundance of genera OTU per sample, and alpha and beta

diversities. The total abundance of genera OTUs across all samples shows that 104D0 and

108D0 had the highest OTU abundance. Only a few genera had significant (t-test) abundance

variation across each sample: 104D1 (p: 0.031), 105D2 (p: 0.2376), 107D2 (p: 0.007), 108D2

(p: 0.0114), 109D2 (p: 0.0178) (A). Wilcoxon's test found all genera abundance to be

significant (p: <0.0001), but they were insignificant by t-test; one- & two-way ANOVA were

both significant. The count of all genera (OTUs) per sample shows sample 108D0 had the

highest number of genera; count per genera was statistically significant (p: <0.0001) (**B**).

Alpha-diversity of each sample is shown in C and they were all significant (p: <0.0001). The

 β -diversities between samples of the same patient are shown in **D**, with the variations

between β -diversities varying per patient (p: <0.0001). β -diversity between baseline (S1) and

day 1 (S2) is shown as blue bars, between baseline and day 2 (S3) is shown as orange bars,

between baseline and day 7 (S4) is shown as grey bars, between days 1 (S2) and 2 (S3) is

shown as yellow bars, between days 1 and 7 is shown as light blue bars, and between days 2

and 7 are shown as green bars. The β -diversity variations between samples collected at the

- same time point (days 0, 1, 2, and 7) from different patients is shown in \mathbf{E} (p: 0.0821;
- <0.0001). S1, S2, S3, and S4 represent days 0 (baseline), 1, 2, and 7 respectively. The β -

diversity variation between samples collected at the same time points, but from different
patients, are shown as coloured bars: blue (baseline), orange (day 1), grey (day 2) and yellow
(day 7).

721 Figure 3. Total abundance of taxonomic Kingdoms per sample. Bacteria was most 722 dominant across all samples except in 107D2, 109D1, 109D2, where Fungi was most 723 dominant. Parasites were also found in substantial proportions in 104D1, 105D2, 107D7, 724 108D1, 108D2, 109D1, 109D2, and 112D2, but viruses and archaea were very minor in 725 abundance in all the samples. Wilcoxon's test showed significance (p: <0.0001) for all 726 kingdoms and 2-Way ANOVA was significant for the samples (A). Among almost all the 727 samples, the bacterial phylum Firmicutes was the most dominant, except in 105D2, 107D2, 728 108D1, and 112D2 where it was almost absent. Actinobacteria was the next dominant 729 phylum, with Proteobacteria, Bacteroidetes and the other phyla occupying a relatively small 730 portion of the microbiota. A reduction in bacterial phyla abundance was seen after the 731 baseline until on day 7, when a rise in abundance was observed again in all the samples (**B**). 732 Figure 4. Abundance and diversity of OTUs in Firmicutes, Proteobacteria, 733 Actinobacteria, Bacteroides and other bacterial orders in sputum samples. A u-shaped 734 pattern was observed among genera in the various phyla: they reduced in abundance after day 735 0 and rose gradually from day 2 to day 7. The diversities reduced or increased depending on 736 the patient. The abundance and diversity of genera found in the phylum Firmicutes is shown 737 in A; Streptococcus was the commonest genus and reduced after baseline but rose gradually 738 from day 2 unto day 7. This u-shaped pattern was observed in other genera under Firmicutes. 739 Abundance and diversity of genera under Proteobacteria are shown in **B**, in which 740 Pseudomonas was the most abundant. Among Actinobacteria (C), Mycobacterium was 741 common, but also reduced drastically after the baseline and hardly rose again, making it the

742 genera most affected by the antibiotics. Bacteroidetes, Cyanobacteria, Tenericutes and other

Phyla with relatively little abundance are shown in **D**. Within these phyla, the u-shaped

pattern was also observed from baseline to day 7, with days 1 and 2 having lowerabundances.

746	Figure 5. Abundance of selected genera in all samples across different sampling-time
747	points. The abundance of Streptococcus (A), Mycobacterium (B), and different sets of
748	selected genera (C, D, E, and F) across different sampling-time points (baseline, day 1, day
749	2, and day 7) showed a reduction in abundance after baseline on days 1 and 2, and a rise on
750	day 7. However, Mycobacterium declined after the baseline and continued declining
751	afterwards. The variations in abundance over sampling time was significant for Streptococcus
752	(p: 0.0078) Granulicatella (p: 0.0432), Clostridium, Lactobacillus (p: 0.0272),
753	Bifidobacterium (p: 0.0071), Bacillus (0.0141) etc. by one-sample t-test, and was significant
754	for almost all the selected genera, including Mycobacterium (p: <0.0001). One-/two-way
755	ANOVA matching of the genera to their abundance were significant (Dataset 3).
756	Figure 6. Abundance of archaea, parasite, fungi, and viral OTUs per sample. The
757	abundance of archaeal OTUs is shown in A where only 108D0 had 4 archaeal genera: Two-
	abundance of alchaear of es is shown in 12, where only 100D0 had a alchaear genera, 140
758	way ANOVA was significant for only the row factor. Both Wilcoxon's and one-sample t-
758 759	way ANOVA was significant for only the row factor. Both Wilcoxon's and one-sample t- tests were insignificant. Abundance of parasites per sample is shown in \mathbf{B} ; parasites were
758 759 760	way ANOVA was significant for only the row factor. Both Wilcoxon's and one-sample t- tests were insignificant. Abundance of parasites per sample is shown in B ; parasites were found in all samples with non-consistent variations in abundance across different sampling-
758 759 760 761	way ANOVA was significant for only the row factor. Both Wilcoxon's and one-sample t- tests were insignificant. Abundance of parasites per sample is shown in B ; parasites were found in all samples with non-consistent variations in abundance across different sampling- time points per patient. Two-way ANOVA column factor was significant. Schistosoma
758 759 760 761 762	way ANOVA was significant for only the row factor. Both Wilcoxon's and one-sample t- tests were insignificant. Abundance of parasites per sample is shown in B ; parasites were found in all samples with non-consistent variations in abundance across different sampling- time points per patient. Two-way ANOVA column factor was significant. Schistosoma (p:0.0014), Moniezia (p:0.0187), Drosophila (p:0.0406), Plasmodium (p:0.0404), &
758 759 760 761 762 763	way ANOVA was significant for only the row factor. Both Wilcoxon's and one-sample t- tests were insignificant. Abundance of parasites per sample is shown in B ; parasites were found in all samples with non-consistent variations in abundance across different sampling- time points per patient. Two-way ANOVA column factor was significant. Schistosoma (p:0.0014), Moniezia (p:0.0187), Drosophila (p:0.0406), Plasmodium (p:0.0404), & Monosiga (p:0.0256) were significant by one-sample & Wilcoxons' tests; Noniella (p:0.0005)
758 759 760 761 762 763 764	way ANOVA was significant for only the row factor. Both Wilcoxon's and one-sample t- tests were insignificant. Abundance of parasites per sample is shown in B ; parasites were found in all samples with non-consistent variations in abundance across different sampling- time points per patient. Two-way ANOVA column factor was significant. Schistosoma (p:0.0014), Moniezia (p:0.0187), Drosophila (p:0.0406), Plasmodium (p:0.0404), & Monosiga (p:0.0256) were significant by one-sample & Wilcoxons' tests; Noniella (p:0.0005) & Codonosigidae (p:<0.0001) were only significant with Wilcoxon's test. The abundance and
758 759 760 761 762 763 764 765	way ANOVA was significant for only the row factor. Both Wilcoxon's and one-sample t- tests were insignificant. Abundance of parasites per sample is shown in B ; parasites were found in all samples with non-consistent variations in abundance across different sampling- time points per patient. Two-way ANOVA column factor was significant. Schistosoma (p:0.0014), Moniezia (p:0.0187), Drosophila (p:0.0406), Plasmodium (p:0.0404), & Monosiga (p:0.0256) were significant by one-sample & Wilcoxons' tests; Noniella (p:0.0005) & Codonosigidae (p:<0.0001) were only significant with Wilcoxon's test. The abundance and variations of 51 fungal OTUs across different sampling-times per patient is shown in C ; 2-
758 759 760 761 762 763 764 765 766	way ANOVA was significant for only the row factor. Both Wilcoxon's and one-sample t- tests were insignificant. Abundance of parasites per sample is shown in B ; parasites were found in all samples with non-consistent variations in abundance across different sampling- time points per patient. Two-way ANOVA column factor was significant. Schistosoma (p:0.0014), Moniezia (p:0.0187), Drosophila (p:0.0406), Plasmodium (p:0.0404), & Monosiga (p:0.0256) were significant by one-sample & Wilcoxons' tests; Noniella (p:0.0005) & Codonosigidae (p:<0.0001) were only significant with Wilcoxon's test. The abundance and variations of 51 fungal OTUs across different sampling-times per patient is shown in C ; 2- Way ANOVA of fungi genera with abundance was insignificant. Also, none of the

(p:0.0078) & Penicillium (p:0.0078). Siphoviridae, Podoviridae, Myoviridae, Retroviridae,

769 Anelloviridae, T4-like, Muromegalovirus, Caudovirales, and Lymphocryptovirus viruses

were the viruses found in mainly baseline and day 7 samples, with 107D2 and 111D1 being

the only samples from days 2 and 1, respectively (**D**). Although the presence of viruses in the

samples were significant (2-Way ANOVA), none of the variations in abundance for every

virus OTU was significant.

774 **Figure 7. Functional component subsystem distribution per sample.** The functional

composition of each sample is shown in **A**, where clustering-based subsystems,

carbohydrates, protein metabolism etc., dominated the samples. The samples with the most

abundant functional subsystems components were mainly baseline and day 7 samples such as

104D0, 108D0, 108D7, 111D7, 112D0, 109D7, 107D7, and 107D0 (B). A sampling time-

point grouping shows that baseline and day 7 samples had the most functional components

whilst days 1 and 2 samples had lower functional components (C). U-shaped patterns were

observed across the sampling points, with abundance of functional components reducing

from baseline to days 1 and 2, and increasing on day 7 (**D**). Functional subsystems

components with the most substantial proportion in all the samples shows that clustering-

based subsystems, carbohydrates, protein metabolism, RNA metabolism, amino acids and

derivates, and DNA metabolism were common subsystems. These varied across the samples

at different sampling points: baseline, day 1, day 2, and day 7 (E). The variations in

abundance for the functional components of each sample was statistically significant; two-

788 way ANOVA was significant.

Figure 8. Nonmetric multidimensional scaling (NMDS) and ordination plots. The

790 microbiota were closely related to each other at baseline, but became less related/connected at

days 1 and 2; the networks between the microbiota increased at day7. The network analysis

of the microbiota between baseline and day 2 is shown in **A** and **B** respectively. The

793 ordination plots showing the spatial relationship between the microbiota are shown in C and

794 **D** respectively.

795 Dataset 1. Patient demographics, sputum sampling, and sputum characteristics

796 Dataset 2. Operational taxonomic units (OTU) abundance per sputum sample, taxonomy,

797 metadata, resistance mechanisms and mobile genetic elements in each sputum sample.

798 **Dataset 3**. Statistical analyses of microbiome OTU data per sample.

799 Figure S1. Total OTU abundance of the various genera across all samples. The total

abundance of each OTU genera across all samples are categorised into four: above 1000 (A),

801 between 1000-100 (**B**), between 100-10 (**C**), and below 10 (**D**). Most genera were below 10

and a few were above 1000.

Figure S2. Chao1 and Shannon alpha diversities of samples according to daily

804 collections and OTU genera categorisation. The Chao1 and Shannon indices differed from

805 each other for the same sample and patient.

806 Figure S3. Abundance of each taxonomic rank, from kingdom to genus, in each sample.

807 A detailed breakdown of each kingdom, phylum, class, order, family, and genus in each

sample across all time points and in only baseline, day 1, 2, and 7 samples are shown in i to
xxx.

810 Figure S4. Abundance of bacterial OTUs per taxonomic rank and sampling-time point

811 per sample. Common bacterial genera included Streptococci, Mycobacterium, Veillonella,

and Pseudomonas. Abundance of each OTU per taxonomic rank and sampling time-points

shows antibiotic-mediated variations from baseline to day 7.

Figure S5. Abundance of parasite OTUs per taxonomic rank and sampling-time point
per sample.

816	Figure S6. Abundance of fungi OTUs per taxonomic rank and sampling-time point per
817	sample.

- Figure S7. Abundance of viral OTUs per taxonomic rank and sampling-time point per
 sample.
- 820 Figure S8. Functional components and subsystems of the various samples. The functional
- components and subsystems shifted in proportion per sample for the different sampling

822 points.

- 823 Figure S9. Network analysis showing the spatial interactions and networking of the
- 824 various microbial components in the sputum microbiota.
- 825 Figure S10. Non-metric multidimensional scaling (NMDS) of the various OTUs showing
- 826 their ordination plots and spatial orientation per kingdom.
- 827
- 828
- 829
- 830
- 831
- 832
- 833





■ (S1-c)+(S1-c) ■ (S2-c)+(S2-c) ■ (S3-c)+(S3-c) ■ (S4-c)+(S4-c)











Muro megalovirus

unclassified (derived from Caudovirales) Lymphocryptovirus





Cla	ass						
	6	۲	Choanoflagellatea	•	Foraminifera	•	Onygenales
0	Alphaproteobacteria	•	Chromadorea	•	Fusobacteriia		Revtraviricetes
	Aconoidasida	۲	Clostridia	0	Gammaproteobacteria	•	Rhabditophora
	Actinobacteria	•	Conoidasida	•	Herviviricetes	•	Saccharomycetes
	Actinomycetia	•	Coriobacteriia	•	Heunggongvirae	•	Saccharomycotina
	Agaricomycetes	•	Cyanophyceae	•	Holozoa	•	Schizosaccharomycetes
	Alphaproteobacteria	•	Cytophagia	•	incertae sedis	•	Sordariomycetes
	Angiosperms		Dehalococcoidetes	•	Insecta	•	Sphingobacteriia
	Aquificae	•	Delta Proteobacteria	•	Kinetoplastea	•	Spirochaetales
	Bacilli	•	Deltaproteobacteria	0	Leotiomycetes	•	Synergistia
	Bacteroidetes	•	Dothideomycetes	0	Leptocardii	•	Thermoleophilia
	Bacteroidia	•	Epsilonproteobacteria	0	Mammalia	•	Tremellomycetes
	Betaproteobacteria	•	Erysipelotrichia	0	Mollicutes	•	Trichozoa
	Caudoviricetes	•	Eurotiomycetes	0	Mucorales	•	Ustilaginomycetes
	Cestoda	•	Fibrobacteria	•	Negativicutes		
	Chloroflexi	•	Flavobacteriia	•	Oligohymenophorea		

Distance

- 0.0 - 0.2

- 0.4

- 0.6

B







			Chromadorea		Commonrotechacteria		Onvoengles
	2010-00-00-00-00-00-00-00-00-00-00-00-00-		Chiomadorea		Gammaproteobacteria		onygenales
•	Alphaproteobacteria	•	Clostridia		Herviviricetes		Opitutae
٠	Aconoidasida	٠	Conoidasida	٠	Heunggongvirae	•	Planctomycetia
•	Actinobacteria		Coriobacteriia	٠	Holozoa		Revtraviricetes
•	Actinomycetia	٠	Cyanophyceae	٠	incertae sedis	٠	Rhabditophora
•	Agaricomycetes	٠	Cytophagia	۲	Insecta		Saccharomycetes
•	Alphaproteobacteria	٠	Dehalococcoidetes	٠	Kinetoplastea		Saccharomycotina
•	Angiosperms	٠	Deinococci	۰	Ktedonobacteria		Schizosaccharomycetes
•	Aquificae	٠	Delta Proteobacteria	•	Leotiomycetes	٠	Sordariomycetes
	Archaeoglobi	٠	Deltaproteobacteria	•	Leptocardii		Sphingobacteriia
•	Bacilli		Dothideomycetes	٠	Mammalia	۲	Spirochaetales
•	Bacteroidetes		Epsilonproteobacteria	٠	Methanococci		Spirochaetia
•	Bacteroidia	٠	Erysipelotrichia		Methanomicrobia	٠	Synergistia
٠	Betaproteobacteria		Eurotiomycetes		Methylacidiphilae		Thermodesulfovibrionia
•	Caudoviricetes	٠	Exobasidiomycetes		Mollicutes		Thermoleophilia
•	Cestoda	٠	Fibrobacteria		Mucorales		Tissierellia
	Chlorobi		Flavobacteriia		Negativicutes		Tremellomycetes
	Chloroflexi		Foraminifera		Nitrospira		Trichozoa
	Choanoflagellatea		Fusobacteriia		Oligohymenophorea		Ustilaginomycetes



-1 0 1 2 -1 0 1 2 -1 0 1 2 -1 0 1 2 NMDS1

0

D

1-

0 -

-1 -

OTUs							
Animalia	Archaea	Bacteria	Bacteria				
		Conception Conception					
1 .							
		Gammäpräntistängeria Gammaproteckaateria					
	Aprix production and a second se						
0-		Ceptonia (construction of the construction of					
Successions		Activitational Activitation and Activitation Activitatio Activitation Activitation Activitation Activitation					
Chromadores "Melotion		Colorentia in the foreign and					
-1-		Gate rice any disclose right in Cylanget y case					
		Cyanophycese Gariffetodocteria					
Chromista	Eukaryota	Fungi	Metazoa				
	Construction	the state of the s					
1-		Excellence -					
		Ecroliomycetes Euroliomycetes					
082		Eurobiomycome Sardanionycome Sardani					
Ž 0-		Sacchar Grind Barry College					
	Holazon	Sixcher omyostins UtsilaginemyoStatish SULLIVERhycetes					
Accessidaseda	Charrolingefistes						
-1-		Sordariomycotes	Lepticardi				
		Jacuna di reculta					
Plantae	Protista	Virus	Virus				
			setter tal-mades:				
1-							
	Caudowricetes						
		Harvistone					
0-		Heurgangvirae					
	Company and	Caudovinigetes					
Angiosperms	•						
	- Chigany managerara						

1 2 -1 0 1 2 -1 0 1 2 -1 NMDS1

Cla	SS						
٠		•	Chromadorea	٠	Gammaproteobacteria		Onygenales
٠	Alphaproteobacteria	٠	Clostridia	٠	Herviviricetes	٠	Opitutae
1.	Aconoidasida	٠	Conoidasida	٠	Heunggongvirae	٠	Planctomycetia
	Actinobacteria	٠	Coriobacteriia	٠	Holozoa		Revtraviricetes
. •	Actinomycetia	٠	Cyanophyceae	٠	incertae sedis		Rhabditophora
٠	Agaricomycetes	٠	Cytophagia	٠	Insecta	٠	Saccharomycetes
٠	Alphaproteobacteria	٠	Dehalococcoidetes	٠	Kinetoplastea	•	Saccharomycotina
٠	Angiosperms		Deinococci	٠	Ktedonobacteria	٠	Schizosaccharomycetes
٠	Aquificae	٠	Delta Proteobacteria	٠	Leotiomycetes	٠	Sordariomycetes
	Archaeoglobi		Deltaproteobacteria	•	Leptocardii	٠	Sphingobacteriia
٠	Bacilli	٠	Dothideomycetes		Mammalia	٠	Spirochaetales
	Bacteroidetes	٠	Epsilonproteobacteria		Methanococci	٠	Spirochaetia
	Bacteroidia		Erysipelotrichia	(2)	Methanomicrobia	٠	Synergistia
٠	Betaproteobacteria	٠	Eurotiomycetes		Methylacidiphilae		Thermodesulfovibrionia
٠	Caudoviricetes		Exobasidiomycetes		Mollicutes		Thermoleophilia
٠	Cestoda		Fibrobacteria		Mucorales	٠	Tissierellia
٠	Chlorobi	٠	Flavobacteriia		Negativicutes	٠	Tremellomycetes
٠	Chloroflexi	٠	Foraminifera		Nitrospira	٠	Trichozoa
	Choanoflagellatea		Fusobacteriia		Oligohymenophorea	٠	Ustilaginomycetes